Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
about
Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trialsDiabetic Retinopathy: Animal Models, Therapies, and PerspectivesNew Diagnostic and Therapeutic Approaches for Preventing the Progression of Diabetic RetinopathyManagement of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled TrialsUpdates on the Clinical Trials in Diabetic Macular EdemaEpidemiology of diabetic retinopathy, diabetic macular edema and related vision lossRole of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implantThe clinical utility of aflibercept for diabetic macular edemaAnti-VEGF Therapy and the Retina: An UpdatePerspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedemaThe role of aflibercept in the management of diabetic macular edemaIndividualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?Treatment of diabetic retinopathy: Recent advances and unresolved challengesDiabetic Macular Edema Pathophysiology: Vasogenic versus InflammatoryAdministration of Traditional Chinese Blood Circulation Activating Drugs for Microvascular Complications in Patients with Type 2 Diabetes MellitusUpdate on corticosteroids for diabetic macular edemaEvidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelinesFusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conberceptDiabetic macular oedema: evidence-based treatment recommendations for Asian countries.Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.Fenofibrate and Diabetic Retinopathy.High-precision, non-invasive anti-microvascular approach via concurrent ultrasound and laser irradiation.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial.Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.New Therapeutic Approaches in Diabetic Retinopathy.Foveal thickness reduction after anti-vascular endothelial growth factor treatment in chronic diabetic macular edema.Demographic features and visual outcomes of patients presenting to diabetic photo-screening and treated for sight threatening retinopathy in Fiji.A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Galectin-1 expression imprints a neurovascular phenotype in proliferative retinopathies and delineates responses to anti-VEGFPro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseasesEfficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysisPanretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical TrialVEGF: From Discovery to Therapy: The Champalimaud Award Lecture.Diabetic Retinopathy: A Position Statement by the American Diabetes Association.Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
P2860
Q26750459-B12A9115-39D3-4DE8-B647-89652ED25247Q26765466-1BE7136B-4E06-4B51-B2DB-2BF94E1038B9Q26765468-2B327F94-BE52-4ED8-AFA3-BCB74CDFE4FEQ26767095-BC61BDAB-BEF1-4B2B-915F-E505370C8A38Q26767100-D4D37BFE-890A-410E-A76A-3E32BAE95DBEQ26775552-CC9DE84D-87CD-4463-A4CD-E27C4557D54CQ26775853-BBAE775D-718C-4B51-BAB4-ECE5FDCA2CB3Q26783575-668049A7-371E-4C72-9912-0A6AC308BDCDQ26784605-2C20289D-F89A-4BDD-A91E-212F99531E58Q26786012-D0E18A9F-DF36-4D76-91C8-0917F6D6D11BQ26798348-3A034018-4449-49CD-9CB4-796DEE896AD2Q26799492-9CF7F493-1D9A-484C-AC8F-F5C76FE3CABEQ26823985-59338505-F4F0-42AF-B075-CC44C36E2F2FQ28066675-2DE2817F-D180-4369-A35E-21DBF217254BQ28067491-4B429F0D-786B-4CDB-AE05-1929C6F00C63Q28070894-7AB9E588-1D03-4893-A653-08355DA6B954Q28072087-242371D9-8AF8-4547-9E86-17A72A0FC183Q28074846-3EBCCBE6-7902-4FE6-8B09-BB333F12373DQ28075473-AF912B75-CE5D-4059-A8DB-7FF8ED1334E9Q28075557-33C78F31-7202-46D1-A7E9-0D120C1A79E1Q30101045-EBC53EF8-7349-451C-B37F-55939B2B33E3Q30244247-5F43F8AE-4144-463C-9746-EFA59EE7907EQ30248492-CE87B51A-5F19-4BA2-8E1A-70B8037F5A98Q30365660-C73B18B8-1779-40EF-AA46-6053231C3A0FQ30490738-2E7F0425-2B0F-49B3-852F-180BABC99D9CQ30491050-2415BD2D-2F6A-41CB-922F-AA4D4929A675Q31018013-F8CA55C5-7AE2-4C77-B369-CF4B8C450F1FQ31155420-0393758F-267F-4651-B48E-925DC12A9383Q33583037-65ADCD80-6993-4423-8538-FAA4DDD99E2EQ33706093-84DDE776-39CA-4724-BE4E-998EE16DD962Q33706122-D1C5275A-F706-4417-AA6C-5B17267B94B8Q33740152-4DC0AF69-6C8A-4E0E-9D31-A5B36D0BF1C6Q33779141-E8467A7D-984E-4AC2-BDB3-AB8CF1E497C7Q33828636-8671C167-A849-455F-8CFB-C03F1CDB8AFCQ33840787-45E9C6A6-CC0B-4F9A-BDEB-D08BED9AAF4EQ33912485-502BF78F-6651-4416-9ACC-5347C317A2DAQ34501650-C6C40868-C13C-4081-9AB1-4C791769244CQ34518374-2218AC0B-26EC-4126-81A8-51CA3D0F379AQ34551730-22CBF87E-3FA7-4B83-8AAC-0282F75CE528Q34558187-220E74BD-3BF1-4FBE-BAA5-B721B57DB88F
P2860
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
@ast
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
@en
type
label
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
@ast
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
@en
prefLabel
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
@ast
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
@en
P2093
P2860
P356
P1476
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
@en
P2093
Adam R Glassman
Allison R Ayala
Andrew N Antoszyk
Bambi Arnold-Bush
Carl W Baker
Dante J Pieramici
David J Browning
Diabetic Retinopathy Clinical Research Network
Frederick L Ferris
Jennifer K Sun
P2860
P304
P356
10.1056/NEJMOA1414264
P407
P577
2015-02-18T00:00:00Z